BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-1819 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-1819\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07688772-1489@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-1819: Phase 3 readout est. (NCT07688772)
DESCRIPTION:SHR-1819\, phase 3.\nStudy: A Clinical Study Evaluating the Eff
 icacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic 
 Rhinitis\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/shr-1819#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07688772
URL:https://assetmemo.bio/drug/shr-1819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321951-1489@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SHR-1819: Phase 2 readout est. (NCT07321951)
DESCRIPTION:SHR-1819\, phase 2\, Atopic Dermatitis.\nStudy: A Study of SHR-
 1819 in Patients With Moderate-to-severe Atopic Dermatitis\nEstimated prim
 ary completion: June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/shr-1819#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07321951
URL:https://assetmemo.bio/drug/shr-1819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309055-1489@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:SHR-1819: Phase 3 readout est. (NCT07309055)
DESCRIPTION:SHR-1819\, phase 3\, Atopic Dermatitis.\nStudy: A Study of SHR-
 1819 Injection in Adolescents With Severe Atopic Dermatitis\nEstimated pri
 mary completion: November 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/shr-1819#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07309055
URL:https://assetmemo.bio/drug/shr-1819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06554509-1489@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:SHR-1819: Phase 2/3 readout est. (NCT06554509)
DESCRIPTION:SHR-1819\, phase 2/3.\nStudy: Clinical Study of the Efficacy an
 d Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis\nE
 stimated primary completion: October 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/shr-1819#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06554509
URL:https://assetmemo.bio/drug/shr-1819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
